Queiroz L P, Weeks R E, Rapoport A M, Sheftell F D, Baskin S M, Siegel S E
University Hospital, UFSC, Florianopolis, SC, Brazil.
Headache. 1996 May;36(5):291-4. doi: 10.1046/j.1526-4610.1996.3605291.x.
Side effects associated with administration of repetitive intravenous dihydroergotamine (DHE) were prospectively studied in 72 patients with chronic daily headache who were hospitalized in a dedicated inpatient headache treatment program. All patients received 11 consecutive doses of DHE, starting with 0.25 mg and increasing by 0.25 mg up to a maximum dose of 1.25 mg, depending on side effects and/or headache relief. The adverse events were recorded after each dose administered. The great majority of patients (91.6%) reported at least one side effect. The most common were: nausea (72.2%), increase in previous headache (47.2%), lightheadedness (33.3%), "new" headache (27.8%), and leg cramps (23.6%). The overall number of side effect complaints did not increase proportionally with the strength of the dose of DHE administered. These complaints declined from the earlier to the later doses of DHE, except for leg cramps, which were more common with the later doses. Side effects determined the strength of subsequent doses of DHE in only 18.1% of patients. Only four patients had to have a decrease in dosage and none required termination of DHE due to side effects. Although repetitive intravenous DHE causes frequent side effects, they are usually mild and transient and decrease with subsequent doses, even at higher doses.
在一个专门的住院头痛治疗项目中，对72例慢性每日头痛患者进行了前瞻性研究，以观察重复静脉注射双氢麦角胺（DHE）的副作用。所有患者连续接受11剂DHE治疗，起始剂量为0.25mg，根据副作用和/或头痛缓解情况，每次增加0.25mg，最大剂量为1.25mg。每次给药后记录不良事件。绝大多数患者（91.6%）报告至少有一种副作用。最常见的副作用是：恶心（72.2%）、原有头痛加重（47.2%）、头晕（33.3%）、“新发”头痛（27.8%）和腿部痉挛（23.6%）。副作用投诉的总数并未随着DHE给药剂量的增加而成比例增加。这些投诉从DHE的早期剂量到后期剂量有所减少，但腿部痉挛除外，后期剂量时更常见。仅18.1%的患者副作用决定了后续DHE的剂量。只有4例患者需要减少剂量，没有患者因副作用而需要终止DHE治疗。尽管重复静脉注射DHE会频繁引起副作用，但这些副作用通常较轻且短暂，即使在较高剂量下，后续剂量时也会减少。
